Overview

  • Product nameUBP141
  • Description
    GluN2D (formerly NR2D) antagonist, with some subunit selectivity
  • Biological descriptionGluN2D (formerly NR2D) antagonist, displaying modest GluN2 (NR2) subunit selectivity. Shows 7-fold selectivity for GluN2D (NR2D)-containing NMDA receptors vs GluN2B (NR2B) and 5-fold selectivity over GluN2A (NR2A ) but does not discriminate between GluN2C (NR2C) and GluN2D (NR2D). Ki values are 22, 17.2, 5.24 and 2.36 μM for NR1/2A, NR1/2B, NR1/2C and NR1/2D receptors respectively.
  • Purity> 98%

Properties

    References for UBP141 (ab120193)

    This product has been referenced in:
    • Costa BM  et al. N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse. J Pharmacol Exp Ther 331:618-26 (2009). Read more (PubMed: 19684252) »
    • Brothwell SL  et al. NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J Physiol 586:739-50 (2008). Read more (PubMed: 18033813) »
    • Morley RM  et al. Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem 48:2627-37 (2005). Read more (PubMed: 15801853) »

    See all 5 Publications for this product

    Product Wall

    There are currently no Questions for ab120193.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"